Abstract:Introduction Cow's milk protein allergy (CMPA) is the most frequent food allergy in early childhood. For those infants requiring breastmilk substitutes, formulas with extensively hydrolyzed proteins (EHF), should be the treatment of choice. As there are limited data showing the progression of initial symptoms in infants newly diagnosed with CMPA who are treated with EHF with added synbiotics, the main objective of this study was to evaluate the resolution of symptoms in said infants after 4 weeks of treatment. As a secondary objective this study aimed to assess the impact of the treatment on the family's quality of life. Materials and Methods observational, longitudinal, prospective, and multicentric real-world evidence study. The intervention phase (EHF with synbiotics) lasted 28 days and was completed by 65 patients. Treating physicians registered child ́s anthropometry, Infant Gastrointestinal Symptoms Questionnaire (IGSQ-13) and CoMiSS (Cow ́s Milk Allergy Symptoms Score) both at baseline and after 28 days of treatment. During treatment, caregivers reported child ́s regurgitation and stools, PO-SCORAD (Patient Oriented Scoring of Atopic Dermatitis) and FAQL-PB (Family Quality of Life—Parental Burden). Data were collected using Google Forms and analyzed through the STATA program. Results 95.4% of the patients showed an improvement or disappearance of the overall initial symptoms after 4 weeks of treatment. Gastrointestinal symptoms improved or disappeared in 92% of patients ( p < 0.05) while dermatological symptoms improved or disappeared in 87.5% of patients ( p < 0.05). The median CoMiSS at baseline was 9, with 21 patients exceeding the cut-off point of 12. After 4 weeks of treatment, the median dropped to 3, and no patient exceeded the 12-cut-off point ( p = 0.000). At baseline, patients had a PO-SCORAD of 11.5 (interquartile range 1–23) that went to 1.0 (interquartile range 1–6) at day 28 ( p = 0.000). The treatment diminished stool frequency ( p < 0.05), improved stool consistency ( p = 0.004) and decreased the frequency of regurgitation in infants with CMPA ( p = 0.01). The percentage of patients who no longer had any episode of regurgitation increased from 11% to 31% on day 28 ( p = 0.003). At baseline, 13% of patients cried more than 3 h per day, while at day 28 that percentage dropped to 3% ( p = 0.03). An improvement in the infants' sleep pattern was also appreciated with the treatment. At study onset, 56% of the families reported feeling very overwhelmed, a percentage that dropped to 17% after 28 days of treatment ( p < 0.05). The small percentage of families who did not feel overwhelmed at study onset (17%), grew to 43% on day 28 ( p < 0.05). Conclusions The use of an EHF with synbiotics for the management of infants diagnosed with or suspected to have CMPA suggested a good safety profile, an adequate infant growth, and improvement of overall, gastrointestinal, and dermatological symptoms. It also suggested a lower daily frequency of regurgitations and stools, and an improvement in stool consistency, sleeping pattern, and quality of life of the infant and his family.

Retrospective Cohort Study Demonstrates Tolerance and Adherence to Pea-Based Complete Enteral Formula When Transitioned from a Previous Hypoallergenic Product

Growth in Infants with Cow's Milk Protein Allergy Fed an Amino Acid-Based Formula.

An extensively hydrolysed casein-based formula for infants with cows' milk protein allergy: tolerance/hypo-allergenicity and growth catch-up

Efficacy of an extensively hydrolyzed formula with the addition of synbiotics in infants with cow's milk protein allergy: a real-world evidence study

Growth pattern of paediatric patients affected by cow milk protein allergy fed with rice hydrolyzed formula

Navigating formula shortages: associations of parental perspectives on transitioning to alternative infant formulas for cow's milk protein allergy during the 2022 national formula shortage

Growth, tolerance and biochemical measures in healthy infants fed a partially hydrolyzed rice protein-based formula: a randomized, blinded, prospective trial

A partially hydrolyzed formula with synbiotics supports adequate growth and is well tolerated in healthy, Chinese term infants: A double-blind, randomized controlled trial

Twelve-month growth and accession of tolerance in infants with cow's milk protein allergy compared among those fed with breast milk or alternative formulae.

Gastrointestinal tolerance of a pediatric fiber formula in developmentally disabled children

Safety and tolerance of a new extensively hydrolyzed rice protein-based formula in the management of infants with cow’s milk protein allergy

A new partially hydrolyzed whey-based follow-on formula with age-adapted protein content supports healthy growth during the first year of life

A partially hydrolyzed whey formula provides adequate nutrition in high-risk infants for allergy

Parenteral nutrition dependence and growth in pediatric patients with intestinal failure following transition to blenderized tube feedings: A case series

Growth in healthy infants with cow's milk protein allergy fed extensively hydrolyzed or amino acid-based formulas

Tolerance of Infants Fed a Hydrolyzed Rice Infant Formula with 2′-Fucosyllactose (2′-FL) Human Milk Oligosaccharide (HMO)

Extensively Hydrolyzed Formula Improves Allergic Symptoms in the Short Term in Infants with Suspected Cow’s Milk Protein Allergy

The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study

Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition

Stool microbiome, pH and short/branched chain fatty acids in infants receiving extensively hydrolyzed formula, amino acid formula, or human milk through two months of age

Tolerance development in cow's milk‐allergic children receiving amino acid‐based formula with synbiotics: 36‐Months follow‐up of a randomized controlled trial (PRESTO Study)